Stephanie Emory explores the pros and cons of various technologies for enhancing solubility and bioavailability for oral drug formulations. Further, Dr Emory draws on her experience as a reviewer at the US FDA to discuss how developers can view the FDA as a partner to aid success when leveraging innovative approaches.
Andrea Cusack discusses how, by using bottom-up nanotechnology techniques, efficiencies can be found both in the development of new chemical entities and in the repurposing of existing drugs, and how these efficiencies translate into reduced energy requirements and therefore more sustainable industry practices.
TFF AND UNION AGREE LICENSING PACT FOR TFF TECHNOLOGY WITH NICLOSAMIDE FOR THE TREATMENT OF COVID-19
Adare Pharma's Maria Flynn talks with ONdrugDelivery about trends in the oral drug development and delivery space, completing the Orbis Biosciences acquisition during a global pandemic, and how the excellent technology portfolio and strategic fit between Orbis and Adare form part of the combined organisation’s unique story.
Dr Batalla introduces the company and describes its Proteoral® technology for the oral delivery of proteins to the bloodstream, therapeutic applications, and products to date. Panarum is an Argentine company and this interview is presented here in Spanish and English, an exciting first for ONdrugDelivery!